<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Biogen-US09062X1037">Biogen</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/19/3258886/0/en/Biogen-to-Present-New-Late-Breaking-Litifilimab-Phase-2-AMETHYST-Data-in-Cutaneous-Lupus-Erythematosus-at-2026-American-Academy-of-Dermatology-Annual-Meeting.html">Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting</a>
    </div>

      <div class="me-0 me-md-5">
        CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31. Late-breaking data from Part A (Phase 2) of the AMETHYST Phase 2/3 study will be presented that highlight litifilimab&#39;s effect on cutaneous lupus erythematosus (CLE) disease a...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Biogen-US09062X1037">Biogen</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Seeking Alpha</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 3 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4883677-biogen-inc-biib-presents-at-stifel-2026-virtual-cns-forum-transcript">Biogen Inc. (BIIB) Presents at Stifel 2026 Virtual CNS Forum Transcript</a>
    </div>

      <div class="me-0 me-md-5">
        Biogen Inc. (BIIB) Presents at Stifel 2026 Virtual CNS Forum Transcript
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Biogen-US09062X1037">Biogen</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">AD HOC NEWS</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.ad-hoc-news.de/boerse/news/ueberblick/biogen-inc-aktie-isin-us09062x1037-frische-sma-daten-und/68675946">Biogen Inc. Aktie (ISIN: US09062X1037) profitiert von neuen Daten zu seiner einmal jährlichen SMA-Therapie salanersen. Institutionelle Investoren wie Legal &amp; General erhöhen Anteile – ein Signal für DACH-Anleger?</a>
    </div>

      <div class="me-0 me-md-5">
        Biogen Inc. Aktie (ISIN: US09062X1037): Frische SMA-Daten und Phase-3-Pläne beleben Pipeline-Hoffnungen
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positiv
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Biogen-US09062X1037">Biogen</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">24/7 Wall Street</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://247wallst.com/investing/2026/03/11/josh-brown-biotech-growth-stocks-immune-to-disruption-risk/?utm_source=snapi">Josh Brown: Biotech growth stocks immune to disruption risk</a>
    </div>

      <div class="me-0 me-md-5">
        Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC&#39;s Halftime Report this week about large-cap biotech: “These are growth stocks where you don&#39;t have to worry about disruption.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Biogen-US09062X1037">Biogen</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/11/3253722/0/en/Biogen-Presents-Additional-Salanersen-Data-Showing-New-Motor-Milestones-Achieved-in-Children-with-SMA-Previously-Treated-with-Gene-Therapy.html">Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy</a>
    </div>

      <div class="me-0 me-md-5">
        New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy Salanersen is a novel antisense oligonucleotide and has the potential to deliver high efficacy in SMA with once-yearly dosing Biogen also debuted the design of the Phase 3 salanersen clinical trial...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Biogen-US09062X1037">Biogen</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Seeking Alpha</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://seekingalpha.com/article/4880646-biogen-inc-biib-presents-at-leerink-global-healthcare-conference-2026-transcript">Biogen Inc. (BIIB) Presents at Leerink Global Healthcare Conference 2026 Transcript</a>
    </div>

      <div class="me-0 me-md-5">
        Biogen Inc. (BIIB) Presents at Leerink Global Healthcare Conference 2026 Transcript
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Biogen-US09062X1037">Biogen</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/05/3250050/0/en/Biogen-to-Share-New-SMA-Data-at-Muscular-Dystrophy-Association-and-SMA-Europe-Conferences.html">Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences</a>
    </div>

      <div class="me-0 me-md-5">
        Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investigational drug that has the potential for high potency with once-yearly dosing CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nas...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Biogen-US09062X1037">Biogen</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260304993138/en/The-New-England-Journal-of-Medicine-Publishes-First-Data-to-Demonstrate-the-Potential-for-Disease-Modification-in-Dravet-Syndrome/">The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome</a>
    </div>

      <div class="me-0 me-md-5">
        BEDFORD, Mass. &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body&#39;s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New England Journal of Medicine (NEJM). The pub...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Biogen-US09062X1037/load_more?page=9">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>